Kura Oncology Reports 86% CR Rate for KOMZIFTI in AML Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 08 2025
0mins
Source: Newsfilter
- Clinical Trial Results: In newly diagnosed NPM1-mutated acute myeloid leukemia (AML) patients, the combination of KOMZIFTI with venetoclax and azacitidine achieved an 86% complete remission (CR) rate, with 68% of patients attaining molecular MRD negativity, demonstrating significant therapeutic efficacy.
- Good Tolerability: The triplet regimen exhibited favorable tolerability in both newly diagnosed and relapsed/refractory patients, not increasing the expected toxicity associated with venetoclax/azacitidine, paving the way for its integration into future front-line and relapsed treatment protocols.
- Ongoing Registrational Trials: Kura Oncology is conducting the KOMET-007 registrational trial to evaluate KOMZIFTI's application in chemotherapy-ineligible patients, further validating its potential in AML treatment.
- Broad Market Potential: As the first oral menin inhibitor approved by the FDA, KOMZIFTI is expected to provide new treatment options for acute myeloid leukemia patients, addressing the urgent market demand for effective therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KURA
Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 29.71 USD with a low forecast of 16.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.220
Low
16.00
Averages
29.71
High
40.00
Current: 8.220
Low
16.00
Averages
29.71
High
40.00
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kura Oncology Reports $2.1M KOMZIFTI Revenue in 2025 Financial Results
- Revenue Highlight: Kura Oncology reported $2.1 million in net product revenue from KOMZIFTI (ziftomenib) during the initial five weeks of commercial availability in its preliminary 2025 financial results, indicating strong market acceptance that is expected to drive future revenue growth.
- Milestone Payments: The company received $195 million in milestone payments from its collaboration with Kyowa Kirin in Q4, further strengthening its financial position and providing funding support for ongoing research and development initiatives.
- Regulatory Approval: KOMZIFTI achieved full FDA approval in 2025 for adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation, marking a significant breakthrough as the first once-daily oral menin inhibitor approved for this indication.
- Future Outlook: Kura aims to accelerate the U.S. uptake of KOMZIFTI in 2026 and plans to present updated data from the KOMET-007 trial in the first half of the year, which will further enhance product penetration and revenue growth.
Continue Reading
Kura Oncology Launches KOMZIFTI, First Once-Daily Oral Menin Inhibitor with $2.1M Initial Revenue
- Product Launch: Kura Oncology's KOMZIFTI™ (ziftomenib), approved by the FDA on November 13, 2025, is the first once-daily oral menin inhibitor designed for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML), marking a significant breakthrough in precision medicine.
- Initial Revenue: The net product revenue of $2.1 million generated in the five-week period from November 21 to December 31, 2025, indicates strong market acceptance and is expected to drive continued growth for the company in 2026.
- Strategic Collaboration: Kura received milestone payments of $195 million under its collaboration agreement with Kyowa Kirin in Q4 2025, further strengthening its financial foundation to support R&D and market expansion plans.
- Future Outlook: Kura anticipates non-cash collaboration revenue recognition of $45 million to $55 million in 2026, combined with $667.3 million in cash and short-term investments as of December 31, 2025, ensuring the ongoing advancement of its ziftomenib program in newly diagnosed AML.
Continue Reading